SCHEMBL1017330

SCHEMBL1017330

CC(=O)c1ccc(-c2ncc3c(n2)CCNC3)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 3/20 0.52
POLB P06746 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
SYK P43405 4/20 0.39
XDH P47989 1/20 0.38
TNKS2 Q9H2K2 1/20 0.37
CYP3A4 P08684 1/20 0.36
MAPKAPK2 P49137 1/20 0.36
WNT1 P04628 2/20 0.36
GSK3B P49841 2/20 0.36
DYRK1A Q13627 2/20 0.36
CLK2 P49760 1/20 0.36
CLK3 P49761 1/20 0.36
PNMT P11086 1/20 0.36
MAP4K1 Q92918 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2B P41595 1/20 0.36
CDK4 P11802 1/20 0.35
CCND3 P30281 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12490852 0.80 HTR2C (0.78) HTR2CPOLBSMN1; SMN2TNKS2CYP3A4
SCHEMBL2793592 0.80 CDK2 (0.48) CDK4CCND3
Hydrochloric Acid SCHEMBL6298979 0.79 HTR2C (0.76) HTR2CPOLBSMN1; SMN2TNKS2CYP3A4
Trifluoroacetic Acid SCHEMBL19664864 0.79 HTR2C (0.62) HTR2CPOLBSMN1; SMN2TNKS2CYP3A4
SCHEMBL16836140 0.78 HTR2C (0.55) HTR2CPOLBSMN1; SMN2TNKS2CYP3A4
SCHEMBL3830137 0.78 HTR2C (0.51) HTR2CPOLBSMN1; SMN2TNKS2CYP3A4
SCHEMBL18549884 0.77 HTR2C (0.50) HTR2CPOLBSMN1; SMN2TNKS2CYP3A4
SCHEMBL12953054 0.75 CYP2C9 (0.40) XDHTNKS2WNT1GSK3BDYRK1A
SCHEMBL18550356 0.75 HTR2C (0.53) HTR2CPOLBSMN1; SMN2TNKS2PNMT
SCHEMBL28745314 0.75 HTR2C (0.48) HTR2CPOLBSMN1; SMN2TNKS2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
EP-1998620-B1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES NEUROGEN CORP (US) 2011-01-12 EP disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
EP-1998620-A4 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES NEUROGEN CORP (US) 2009-09-02 EP disclosed
EP-1998620-A2 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES Neurogen Corporation (US) 2008-12-10 EP disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
WO-2007106349-A2 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues HRH3, HRH4, HRH1 HTR2C 54/4885POLB 3403/4885SMN1; SMN2 1615/4885
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 HTR2C 54/4885POLB 3403/4885SMN1; SMN2 1615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.